Vasomune Therapeutics Overview
- Founded
-
2012
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$2.8M
- Investors
-
6
Vasomune Therapeutics General Information
Description
Operator of a biotechnology platform intended to help with the treatment of target diseases associated with vascular dysfunction and destabilization. The company's drug candidate targets a signaling molecule in the vasculature responsible for regulating barrier defense and the host vascular response to injury, enabling doctors to help patients to fight against illness by modifying the cellular response to disease.
Contact Information
Website
www.vasomune.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 180 John Street
- Suite 305
- Toronto, Ontario M5T 1X5
- Canada
+1 (647) 000-0000
Vasomune Therapeutics Timeline
Vasomune Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Grant | 08-Nov-2021 | $2.8M | 00.00 | Completed | Generating Revenue | |
| 3. Grant | 08-Nov-2021 | 00.00 | 00.00 | Completed | Generating Revenue | |
| 2. Grant | 18-Aug-2020 | $2.79M | $1.5M | Completed | Generating Revenue | |
| 1. Seed Round | 20-Oct-2014 | $1.5M | $1.5M | Completed | Startup |
Vasomune Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Vasomune Therapeutics Patents
Vasomune Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4132491-A2 | Coronavirus therapeutics and treatment methods | Pending | 06-Apr-2020 | 000000000 | |
| AU-2021251096-A1 | Coronavirus therapeutics and treatment methods | Pending | 06-Apr-2020 | 000000000 | |
| CA-3171449-A1 | Coronavirus therapeutics and treatment methods | Pending | 06-Apr-2020 | 000000000 | |
| US-20230028130-A1 | Coronavirus therapeutics and treatment methods | Pending | 06-Apr-2020 | A61K38/08 | 0 |
Vasomune Therapeutics Executive Team (6)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Steven Chackowicz | Business Development Executive | ||
| Douglas Hamilton | Chief Executive Officer & President | ||
| Parimal Nathwani | Chairman |
Vasomune Therapeutics Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| Meenu Chhabra | Self | Board Member | 000 0000 |
| Michael Young | Self | Board Member | 000 0000 |
| Niclas Stiernholm Ph.D | Self | Board Member | 000 0000 |
| Parimal Nathwani | Self | Chairman | 000 0000 |
Vasomune Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Vasomune Therapeutics Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| NRC-IRAP | Government | 000 0000 | 000000 0 | ||
| Ontario Bioscience Innovation Organization | Not-For-Profit Venture Capital | 000 0000 | 000000 0 | ||
| United States Department of Defense | Government | 000 0000 | 000000 0 | ||
| Ontario Genomics | Corporation | Minority | 000 0000 | 000000 0 | |
| Sunnybrook Research Institute | University | Minority | 000 0000 | 000000 0 |